John Moore
Senior Director - Translational Gene Editing Eli Lilly
John Moore is a highly motivated scientist with extensive expertise in in vivo genome engineering, including technologies such as meganucleases, CRISPR/Cas9, TALENS, and ZFN, as well as AAV. His background spans immunity, cancer, development, phenotypic characterization, and molecular biology. As a multidisciplinary team leader, John is dedicated to developing nuclease-based therapeutic platforms. He is experienced in managing projects and personnel, conducting bench research, teaching, and effectively communicating complex scientific concepts to diverse audiences.
Seminars
Securing regulatory approval for novel genome editing modalities presents unique challenges, with unclear expectations around preclinical pharmacology, toxicity and analytics from agencies. Join this workshop to explore how late-stage and commercial companies are structuring IND packages, bridging preclinical and clinical data, and collaborating directly with regulators. Gain robust strategies to accelerate your program into the clinic.
Workshop highlights:
- Examining how late-stage companies structure IND packages for novel genome editing modalities, helping you build stronger regulatory submissions faster
- Identifying which preclinical outcomes most reliably predict clinical success, enabling you to design more robust studies that satisfy regulatory scrutiny
- Exploring commercial-stage regulatory strategies across new genome editing tools, giving you a roadmap to navigate approval pathways with greater confidence
- Engaging regulators directly in panel discussion to surface industry best practices, empowering you to foster more productive agency relationships for your program
